Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 30, 2017, by Jazz Pharmaceuticals Plc, an Ireland-based biopharmaceutical company. The report discloses significant changes in executive leadership effective January 3, 2018.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure: Russell J. Cox resigned as Executive Vice President and Chief Operating Officer, effective January 3, 2018.
- Appointment: Daniel N. Swisher, Jr. was appointed as President and Chief Operating Officer, effective January 3, 2018.
- Compensation Package for Mr. Swisher:
- Annual Base Salary: $625,000.
- Target Bonus: 55% of annual base salary.
- Signing Bonus: $125,000.
- Equity Grants: Option to purchase 45,000 ordinary shares and 18,000 restricted stock units (RSUs).
Outlook, Risks, and Management Commentary
The filing details Mr. Swisher's background, including his tenure as CEO of Sunesis Pharmaceuticals, Inc., and his board roles at Cerus Corporation and Corcept Therapeutics, Inc. The company expects Mr. Swisher to enter into a standard indemnification agreement. No specific financial guidance, risks, or contingencies are disclosed in this document.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (January 3, 2018).
- Verify the vesting schedules for the 45,000 stock options (25% at one year, remainder over 36 months) and 18,000 RSUs (four equal annual installments).
- Review the terms of the 2011 Equity Incentive Plan and Severance Plan referenced for potential vesting acceleration.
- Assess the impact of the executive change on the company's strategic direction, as no operational metrics are provided in this filing.